依达拉奉治疗急性脑出血的临床疗效评价

目的 评价依达拉奉治疗急性脑出血的临床疗效.方法 将86例急性脑出血患者随机分为观察组(n=46)和对照组(n=40).两组均给予常规治疗,观察组加用依达拉奉静脉滴注,治疗4周.观察神经功能缺损评分和日常生活活动能力评分及脑血肿和水肿体积变化.结果 治疗4周后观察组神经功能缺损评分的降低和治疗2、4周后日常生活活动能力评分的提高与对照组比较差异均有显著性(P<0.05);治疗4周后观察组血肿体积、治疗2周和4周后观察组水肿体积与对照组比较差异有显著性(P<0.05);治疗后4周观察组的总有效率高于对照组(P<0.05);两组不良事件的发生率无明显差异.结论 依达拉奉能改善急性脑出血患者的神经功能缺损和日常生活活动能力水平,促进血肿吸收和抑制水肿形成,是治疗急性脑出血安全有效的药物.

Evaluation of Clinical Efficacy of Acute Cerebral Hemorrhage of Edaravone

Aim To evaluate the clinical efficacy of the treatment of acute cerebral hemorrhage of edaravone in-jection. Methods 86 patients with acute cerebral hemorrhage were randomly divided into observation group ( n = 46 ) and control group ( n = 40 ). The two groups were given conventional therapy, but the observation group added with intra-venous infusion edaravone for four weeks. Neurologic impairment score, daily life activites ability score, hematoma vol-ume and edema volume were observed. Results The differences of decrease of neurologic impairment score after 4 weeks treatment and the improvement of daily life activities ability score after 2 and 4 weeks treatment of the observation group were statistically significant compared with control group ( P < 0. 05 ) ;the differences of hematoma volume after 4 weeks treatment and the edema volume after 2 and 4 weeks treatment of the observation group were statistically significant compared with the control group ( P < 0.05 ) ;the total efficiency of the observation group after 4 weeks treatment was high-er than that of control group ( P < 0.05 ). The occurrence rate of the two group adverse events were the same. Con-dusion Edaravone is a safe and effective drug to the treatment of acute cerebral hemorrhage, which can improve neurolog-ic impairment and the level of activities of daily life of the patients with acute cerebral hemorrhage, and promote hematoma absorption and restrain edema formation.